Table 1.
Natural product and trial number | L/Lca (%) | AR/ARcb (%) | Mean L/Lc (%) | Mean AR/ARc (%) |
---|---|---|---|---|
Khellin | ||||
Trial 1 | 121.7 | 94.1 | 114.7 ± 9.2 | 97.5 ± 8.0 |
Trial 2 | 112.6 | 101.6 | ||
Trial 3 | 109.7 | 96.6 | ||
Artemisinine | ||||
Trial 1 | 101.0 | 106.8 | 103.9 ± 3.6 | 106.0 ± 2.1 |
Trial 2 | 106.0 | 106.5 | ||
Trial 3 | 104.8 | 104.7 | ||
Beta-lapachone | ||||
Trial 1 | 103.7 | 98.6 | 102.9 ± 5.3 | 98.9 ± 3.9 |
Trial 2 | 100.4 | 99.3 | ||
Trial 3 | 104.7 | 98.9 | ||
Lonchocarpic acid | ||||
Trial 1 | 102.7 | 109.5 | 101.4 ± 2.8 | 111.5 ± 2.7 |
Trial 2 | 101.5 | 112.0 | ||
Trial 3 | 99.9 | 113.0 | ||
Castanospermine | ||||
Trial 1 | 99.9 | 100.3 | 101.0 ± 4.8 | 98.9 ± 4.5 |
Trial 2 | 100.9 | 100.3 | ||
Trial 3 | 102.0 | 96.3 | ||
Curcumin | ||||
Trial 1 | 101.4 | 103.9 | 100.5 ± 5.0 | 101.6 ± 4.5 |
Trial 2 | 101.9 | 99.8 | ||
Trial 3 | 98.2 | 101.0 | ||
Glaucarubine | ||||
Trial 1 | 92.6 | 102.5 | 98.1 ± 6.6 | 100.9 ± 4.3 |
Trial 2 | 101.2 | 101.2 | ||
Trial 3 | 100.5 | 99.2 | ||
Triptolide | ||||
Trial 1 | 97.3 | 101.5 | 98.0 ± 5.8 | 99.3 ± 7.5 |
Trial 2 | 98.5 | 96.9 | ||
Trial 3 | 98.1 | 99.6 | ||
Parthenolide | ||||
Trial 1 | 103.4 | 89.6 | 98.0 ± 4.9 | 91.4 ± 2.8 |
Trial 2 | 94.6 | 91.8 | ||
Trial 3 | 95.9 | 92.7 | ||
Michellamine B | ||||
Trial 1 | 94.5 | 90.3 | 97.0 ± 2.5 | 92.9 ± 3.4 |
Trial 2 | 98.0 | 95.1 | ||
Trial 3 | 98.5 | 93.3 | ||
Tetrocarcin A | ||||
Trial 1 | 96.2 | 99.7 | 96.7 ± 1.6 | 99.4 ± 2.7 |
Trial 2 | 95.9 | 100.2 | ||
Trial 3 | 98.0 | 98.2 | ||
Bactobolin | ||||
Trial 1 | 95.7 | 99.3 | 92.2 ± 6.3 | 97.6 ± 2.9 |
Trial 2 | 95.8 | 97.2 | ||
Trial 3 | 85.0 | 96.4 | ||
Phleomycin [7] | 157.9 ± 17.5 | 64.6 ± 13.1 |
aL/Lc = mean length of NP-exposed cells divided by mean length of control cells (not exposed to NP), as a percentage. Both NP-exposed and control measurements were performed in triplicate
bAR/ARc = mean aspect ratio of NP-exposed cells divided by mean length of control cells (not exposed to NP), as a percentage